Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | HTR1F | P30939 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20307301 | 0.89 | HTR6 (0.81) | HTR6HTR2AHTR2CHDAC1HDAC10 | |
| SCHEMBL12558496 | 0.88 | HTR6 (0.74) | HTR6 | |
| SCHEMBL24877710 | 0.86 | HTR6 (0.69) | HTR6HDAC1HDAC10HDAC8HDAC6 | |
| SCHEMBL31544897 | 0.85 | HTR6 (0.71) | HTR6HTR2AHTR2C | |
| SCHEMBL17943731 | 0.84 | HTR6 (0.69) | HTR6HTR2AHTR2C | |
| SCHEMBL30808104 | 0.83 | HTR6 (0.66) | HTR6HDAC1HDAC10HDAC8HDAC6 | |
| SCHEMBL24877423 | 0.83 | HTR6 (0.66) | HTR6HDAC1HDAC10HDAC8HDAC6 | |
| SCHEMBL12558479 | 0.83 | PADI4 (0.55) | HTR6HTR2A | |
| Ammonia Solution, Strong SCHEMBL15466974 | 0.81 | PADI4 (0.53) | HTR6HTR2A | |
| SCHEMBL4535061 | 0.80 | HTR2A (0.65) | HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885HTR2A 34/4885HTR2C 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.